SYS-CON MEDIA Authors: Michael Bushong, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

China Pharma Holdings Announces Updated Dial-in Information for Its Fiscal Year 2013 Earnings Conference Call

HAIKOU CITY, China, March 21, 2014 /PRNewswire/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE MKT: CPHI), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, announced today updated dial-in information for its fiscal year 2013 earnings conference call. Below is the updated information.

Fiscal Year Conference Call

Date:



Friday, March 21, 2014

Time:



8:30 a.m. ET

Dial#:



US Toll Free: 1 800 742 9301
International: +65 3158 0667
Conference ID 8557805

Webcast:



www.chinapharmaholdings.com

Replay

Dial#:



US Toll Free: 1 855 452 5696
International: +61 2 81990299

Conference ID 8557805

A replay of the call will be accessible through March 28, 2014.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

China Pharma Holdings, Inc.
86-898-66811730
[email protected]

SOURCE China Pharma Holdings, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.